Orchid Pharma Ltd (ORCHPHARMA) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Orchid Pharma reported Q4 sales of Rs. 237 crores, a 9% YoY increase, and full-year sales of Rs. 922 crores, a 13% YoY increase. Full-year EBITDA reached Rs. 156 crores compared to Rs. 140 crores last year.
- These results were achieved despite a Rs. 6 crore one-time expense in Q3 for GMP inspections and a Rs. 9 crore operating loss from the Antimicrobial Solution (AMS) division.
- Both European and US GMP inspections were completed successfully.
- The AMS division, while still in its build-out phase, incurred a Rs. 9 crore EBITDA loss and is expected to remain a drag for two more years.
- The company anticipates a muted FY26 due to pricing pressure and increased CAPEX on the 7-ACA facility, but maintains its mid-teen margin target.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.